Skip to main content
. Author manuscript; available in PMC: 2022 Apr 1.
Published in final edited form as: Pharmacotherapy. 2021 Mar 18;41(4):405–420. doi: 10.1002/phar.2512

Table 8:

Normalized PK Parameters to GW Pharmaceuticals’ PopPK model (1500 mg)

Data points Dose-normalized Cmax (ng/mL) Tmax (hrs) Dose-normalized AUC(0-∞) (h*ng/mL)

Predicted Fasted 335.4 3.5 2198
Predicted Fed 1628 3 8669

A1 672.4 5.12 3366.6
A2 524.5 6.13 2713
A3 142.3 4.07 763.43
B1 840 5 -
B2 852 4.5 -
B3 838 5 -
C 146.063 3 -
D1 75 1 465
D2 315 3 1035
E1 679.5 3 26400
E2 414.56 3 16256.25
F1 375 1.63 64099.5
F2 453 2.8 61168.5
F3 391.5 2.05 74547
F4 370.5 1.27 54306
G 810 1.38 -
H1 292.4 4 1618
H2 266.5 5 1401
H2 240.7 5 1154
H4 195.5 5 975
H5 335.4 3.5 2198
H6 1628 3 8669
H7 581.6 3 -
H8 361.8 3 -
I2 560 1.88 75066.67
I2 910 2.05 118583.33
I3 706.67 2.17 95333.33
I4 1293.33 1.83 181083.33
J1 483 3 1546.5
J2 711.6 3.5 2295.6
J3 307.5 3.5 1171.5
K1 117 1 498
K2 172.5 1.38 846
K3 162.75 1 996
K4 147 1.64 -
K5 171 1.27 -
K6 241.5 2 -
L1 1747.5 2.8 5242.5
L2 2655 2 8722.5
L3 2857.5 2.5 18292.5
L4 1110 2.33 3555
M1 45 3.2 795
M2 675 2.4 3855
N 499.5 4.22 6466140

Dose- and patient weight-normalized values correspond to the Population Pharmacokinetic (PopPK) plot generated by GW Pharmaceuticals